Combined Therapeutics (CTx) has developed a unique modified mRNA platform combining an increased safety profile together with powerful efficacy, to advance the next generation of vaccines accomplished through controlled biodistribution that targets protein expression to specific tissues while reducing off-target effects. Together with our partners, we are committed to using our platform to protect all populations (including those most vulnerable) from global infectious disease threats as well as to treat cancer.